Patents by Inventor Michael Weinfeld

Michael Weinfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220306603
    Abstract: The current application relates to pyronaridine or 6-chloro-2-methoxyacridine analogs having binding affinity for the ERCC1-XPF hetero-dimerization interface. The compounds can be used for targeting DNA repair in tumor cells via ER-CC1-XPF inhibition, therefore improving the therapeutic benefit of irradiation or other cancer treatment, or reducing the dosage and adverse effects associated with such treatment.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Frederick WEST, Jack TUSZYNSKI, Michael WEINFELD, Khaled Hassan BARAKAT, Ahmed H. ELMENOUFY, Francesco GENTILE, Feridoun KARIMI-BUSHERI, Claudia WEILBEER
  • Publication number: 20220249710
    Abstract: Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Inventors: Piyush KUMAR, Hassan ELSAIDI, Leonard Irving WIEBE, Michael WEINFELD, Carolynne Lacar RICARDO
  • Patent number: 11325905
    Abstract: There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 10, 2022
    Assignee: The Governors of the University of Alberta
    Inventors: Dennis Hall, Michael Weinfeld, Sylvain Bernard, Tristan Verdelet, Timothy Morgan, Vikie Lamontagne, Zahra Shire, Afsaneh Lavasanifar
  • Publication number: 20200276338
    Abstract: Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.
    Type: Application
    Filed: September 19, 2018
    Publication date: September 3, 2020
    Inventors: Piyush KUMAR, Hassan ELSAIDI, Leonard Irving WIEBE, Michael WEINFELD, Carolynne Lacar RICARDO
  • Publication number: 20200216486
    Abstract: Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of substituted or unsubstituted 2/4/5-substituted nitroimidazoles, or substituted benzotriazene-1,4-dioxides, or substituted 1,2,3/1,2,4-triazoles, or substituted 1,4-benzoquinones, or a combination of two homo-or hetero BA moieties, wherein linker arm contains C1-16 alkane, alkene, alkyne, alicyclic or aromatic linkers with or without hetero atoms as in ethers, amine, esters, acid, amides, 5 and 6 membered sugar sings with the substitution as described above, both monosaccharides and disaccharides, wherein mapping click contains one of substituted or unsubstituted —N3-, CN, SCN, substituted alkynes for click chemistry.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 9, 2020
    Inventors: Piyush KUMAR, Hassan ELSAIDI, Leonard Irving WIEBE, Michael WEINFELD
  • Publication number: 20200148675
    Abstract: There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.
    Type: Application
    Filed: April 5, 2018
    Publication date: May 14, 2020
    Inventors: Dennis HALL, Michael WEINFELD, Sylvain BERNARD, Tristan VERDELET, Timothy MORGAN, Vikie LAMONTAGNE, Zahra SHIRE, Afsaneh LAVASANIFAR
  • Patent number: 10087448
    Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 2, 2018
    Assignees: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
    Inventors: Michael Weinfeld, Todd Randall Mereniuk, Edan Foley, Dennis G. Hall
  • Patent number: 9694073
    Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: July 4, 2017
    Assignees: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
    Inventors: Michael Weinfeld, Dennis G. Hall, Feridoun Karimi-Busheri, Gary Kenneth Freschauf, Todd Randall Mereniuk
  • Publication number: 20160083732
    Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).
    Type: Application
    Filed: June 30, 2015
    Publication date: March 24, 2016
    Inventors: Michael WEINFELD, Todd Randall MERENIUK, Edan FOLEY, Dennis G. HALL
  • Publication number: 20150306219
    Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
    Type: Application
    Filed: April 30, 2015
    Publication date: October 29, 2015
    Inventors: Michael WEINFELD, Dennis G. HALL, Feridoun KARIMI-BUSHERI, Gary Kenneth FRESCHAUF, Todd Randall MERENIUK
  • Patent number: 9115406
    Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: August 25, 2015
    Assignees: THE GOVENORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
    Inventors: Michael Weinfeld, Todd Randall Mereniuk, Edan Foley, Dennis G. Hall
  • Patent number: 9040551
    Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignees: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA, ALBERTA HEALTH SERVICES
    Inventors: Michael Weinfeld, Dennis G. Hall, Feridoun Karimi-Busheri, Gary Kenneth Freschauf, Todd Randall Mereniuk
  • Publication number: 20130289095
    Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).
    Type: Application
    Filed: November 7, 2011
    Publication date: October 31, 2013
    Applicant: The Governors of the University of Alberta
    Inventors: Michael Weinfeld, Todd Randall Mereniuk, Edan Foley, Dennis G. Hall
  • Publication number: 20120142721
    Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.
    Type: Application
    Filed: June 4, 2010
    Publication date: June 7, 2012
    Applicants: ALBERTA HEALTH SERVICES, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Michael Weinfeld, Dennis G. Hall, Feridoun Karimi-Busheri, Gary Kenneth Freschauf, Todd Randall Mereniuk
  • Patent number: 6132968
    Abstract: The present invention provides methods for the detection and quantitation of any modification of interest in any nucleic acid sequence. In particular, the invention provides methods for detecting and quantitating low levels of modifications of interest in DNA sequences. The methods of the invention take advantage of combining the use of nucleic acid sequence modification-specific molecules which are specific for DNA modifications, of fluorescently labelled proteins which are specific for the nucleic acid sequence modification-specific molecules, of capillary electrophoresis and of laser-induced fluorescence. The methods of the invention are useful for identifying and detecting exposure to carcinogens, in early risk assessment for cancer, and in monitoring of cancer therapy.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: October 17, 2000
    Assignee: University of Alberta
    Inventors: Xiao-Chun Le, Michael Weinfeld, James Z. Xing